Search Results

You are looking at 51 - 60 of 173 items for :

  • "BRAF mutation" x
  • Refine by Access: All x
Clear All
Full access

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Presented by: Dara L. Aisner and Gregory J. Riely

in 5% to 7%, ROS1 rearrangements in 1% to 3%, and BRAF mutations in 2% to 5%. “The best therapeutic outcome is seen if therapy is targeted to the first 3 mutations— EGFR , ALK , and ROS1 . It is critically important to perform testing for

Full access

Oncology Research Program

: Determine the objective response rate of the combination sorafenib and temsirolimus in I-131 refractory thyroid cancer Secondary Outcome Measures: Evaluate if the presence of BRAF mutations, with or without concomitant mutations in the PI3K AKT, mTOR

Full access

NCCN Guidelines Insights: Melanoma, Version 3.2016

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

with single-agent ipilimumab. Both these trials also showed substantially increased toxicity with immune checkpoint combination therapy versus monotherapy. Anti–PD-1 Therapy in Patient Subpopulations: BRAF Mutation Status: Subgroup analyses in the

Full access

Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era

Shailender Bhatia and John A. Thompson

V600R). 25 The absolute and relative frequencies of the different mutations of BRAF are age-dependent, with an inverse relationship between age and BRAF mutation rate and a higher proportion of V600K mutations in older patients. 26 Earlier

Full access

How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?

Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar

cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 26. Hutchins G Southward K Handley K . Value of mismatch repair, KRAS, and BRAF mutations in predicting

Full access

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski

with BRAF mutation–positive DTCs that are locally recurrent, advanced, and/or metastatic, are not surgically resectable, are not amenable to RAI, and are progressing and/or symptomatic (see PAP-9, page 1433). The decision was made to not specify BRAF

Full access

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas

Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park

); only 1 of the 17 patients had a BRAF mutation, and no patients had mutations in HRAS, KRAS, NRAS , or FGFR1 on targeted analysis. 18 Frequent MAPK pathway activation through fusion and nonfusion mutations has been recognized as a potential target

Full access

Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer

Axel Grothey and Alan P. Venook

from the IDEA study for adjuvant treatment of colon cancer. advanced disease. Tumors should be evaluated for KRAS, NRAS , and BRAF status, either individually or as part of a next-generation sequencing panel. KRAS and BRAF mutations are

Full access

A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

neurodegenerative dementia 22 but are not well-associated with human cancer. According to several studies, approximately 1% of GISTs possess BRAF mutations, which are most often canonical V600E seen in other tumor types, including melanoma and colon cancer. 3

Full access

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

anti-EGFR therapy in patients with tumors harboring KRAS, NRAS , and BRAF mutations, which are commonly enriched within the right-sided primary population. 25 – 27 When stratified for sidedness, prospective targeted sequencing panels have revealed